Clinical Trial VICCURO1260


A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Principal Investigator(s)

Christina Derleth


  • Protocol No. VICCURO1260
  • Open Date: 03/19/2013
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the combination of cabazitaxel and mitoxantrone/prednisone as chemotherapy for patients with metastatic CRPC who have not received prior chemotherapy for metastatic disease.
  • Disease Sites: Phase I; Prostate
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Cabazitaxel; Mitoxantrone; Pegfilgrastim; Prednisone
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01594918
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.